The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. (Q42715682)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Alzheimer's disease

0 references

0 references

1 reference

based on heuristic

inferred from title

Christian Hölscher

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Meghan Coakley McCarthy

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Caitriona M Long-Smith

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Sean Manning

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Paula L McClean

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Domhnall J O'Halloran

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

21 September 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

NeuroMolecular Medicine

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

102-114

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23011726%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

https://scigraph.springernature.com/pub.10.1007/s12017-012-8199-5

0 references

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Alzheimer's disease is type 3 diabetes-evidence reviewed

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Neurodegeneration and neurogenesis: focus on Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Glucose metabolism and insulin receptor signal transduction in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Co-expression of multiple transgenes in mouse CNS: a comparison of strategies.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Incretin-based therapies for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Adiposity, type 2 diabetes, and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Endogenous GLP-1 modulates hippocampal activity in beta-amyloid protein-treated rats.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Endogenous GLP-1 is involved in beta-amyloid protein-induced memory impairment and hippocampal neuronal death in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

The glucagon-like peptides: a double-edged therapeutic sword?

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71-year-old men.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes?

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway.

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

mTOR links incretin signaling to HIF induction in pancreatic beta cells

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8199-5

21 January 2018

Amyloid beta oligomers induce impairment of neuronal insulin receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011726

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011726

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011726

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011726

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011726

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p70 S6 kinase and tau in Alzheimer's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011726

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23011726

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42715682&oldid=1581667095"